Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase 1 Safety and Relative Bioavailability Study of DWRX5003 in Healthy Adults
NCT07539415Phase 1Recruiting
- Sponsor
- Daewoong Pharmaceutical
- Start
- May 2026
- Primary completion
- Oct 2026
- Modality
- Peptides
- Countries
- 1
01
Overview
Phase 1, randomised trial of semaglutide buccal patch (BUCCAL-PEP) in obesity and type 2 diabetes mellitus (T2DM) (4 arms), sponsored by Daewoong Pharmaceutical. Primary endpoints: Area Under the Concentration-Time Curve From Time Zero to Time t at 672 hours and Maximum Observed Plasma Concentration at 672 hours. Started May 2026; status: recruiting.
02
Drugs
semaglutide buccal patch (BUCCAL-PEP)
03
Conditions
obesitytype 2 diabetes mellitus (T2DM)
Beyond the preview
Go deeper on NCT07539415.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07539415.